Shandong Lukang Pharmaceutical600789.SHValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 19, 2026, Shandong Lukang Pharmaceutical (600789.SH) trades at a P/E of 56.00x, P/B of 1.54x, P/S of 1.24x, and a dividend yield of 0.65%.
Longitudinal percentile comparison: P/E sits at the 60th percentile over the trailing 10Y window (vs. 76th percentile over 3Y); P/B sits at the 7th percentile over the trailing 10Y window (vs. 23rd percentile over 3Y); P/S sits at the 33rd percentile over the trailing 10Y window (vs. 49th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 64th percentile within its industry and the 64th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.65%, ranking at the 73rd percentile over the trailing 20Y window.
Notably, P/E and P/B aren't telling quite the same story, 53.1 points apart — worth checking the full percentile matrix on this page for the complete picture. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Shandong Lukang Pharmaceutical operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: SHA: 600789 · SSE: 600789 · 600789
Want the full picture on whether Shandong Lukang Pharmaceutical (600789.SH) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 56.00 | ||||||
| P/B (MRQ) | 1.54 | ||||||
| P/S (TTM) | 1.24 | ||||||
| Dividend Yield | 0.65% | ||||||
| Buyback + Div Yield | 0.65% |